Edwards Lifesciences (EW) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Edwards Lifesciences (EW) Reports In-Line Q3 EPS
October 26, 2016 9:20 AM EDT
Stifel analyst Rick Wise lowered his price target on Edwards Lifesciences (NYSE: EW) to $114.00 (from $122.00) following results but maintained a Buy rating.
Wise commented, "While roughly matching both our projections and company guidance, EW's 3Q sales results -- specifically the critical THVT (Transcatheter Heart Therapy) franchise -- fell short of Street expectations by ~$15M (or 4%). Already down in the aftermarket, EW shares undoubtedly will trade lower tomorrow as well, in our view. Despite this shortfall relative to... More
October 26, 2016 8:57 AM EDT
BTIG affirms Edwards Lifesciences (NYSE: EW) with a Buy rating and sets a price target of $110 on the stock following Q3 results.
The firm commented today: Expectations were lofty after multiple beats including Q2 THVs that blew away expectations. We and most others... More
